Why Is MEDLINE INC A (MDLN) Stock Down Today?

MDLN stock fell 16.35% to $35.16 in Monday trading after the company released second-quarter results that included a significant drop in net income. Despite beating revenue and earnings estimates and raising its full-year guidance, the stock opened with a small gap up before declining sharply throughout the session. The decline was likely influenced by a combination of profit-taking, mixed market reactions to the earnings report, and broader market sentiment.

What Happened

Medline Inc. reported second-quarter net sales of $7.7 billion, up 11.6% year-over-year. Adjusted EBITDA increased 13.4% to $1.1 billion. However, net income fell 58.3% to $139 million. The company attributed this to one-time headwinds and updated its full-year guidance. The results were disclosed in a Form 8-K filed with the SEC and presented in a slide deck published by the company. Medline also highlighted strong top-line growth and operational resilience in the face of supply chain challenges.

Recent insider transactions include a sale by the Chief Commercial Officer on June 16 and a purchase by the Principal Accounting Officer on June 5. Over the past 90 days, insiders have sold $3.6 billion worth of shares and bought $171,000.

What The Data Shows

MDLN opened at $42.43, a 0.9% gap up from the prior close, but fell to a session low of $35.05 before closing at $35.16. The stock traded 6.2 million shares, which is 0.7 times the 3-month average. Over the past 8 sessions, the stock had risen 6.5% from $38.75 to $41.26. The stock is currently within its 52-week range of $32.81 to $50.88 and has a market cap of $34.2 billion. It trades at a P/E of 36.8, with trailing 12-month revenue growth of 12.1% and a net margin of 3.3%.

What To Watch

The stock has no scheduled earnings report in the near term. Investors should monitor coverage breadth and market reactions to the earnings report and guidance update.